Trial Profile
A Double-Blind Study Evaluating the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion 0.05% [Restasis] in Subjects With Epiphora Secondary to Docetaxel [Taxotere] Treatment for Various Cancers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 22 May 2014
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Ciclosporin (Primary) ; Fluorometholone; Fluorometholone
- Indications Epiphora
- Focus Therapeutic Use
- Sponsors Allergan
- 22 May 2014 New trial record
- 29 Mar 2010
- 19 Mar 2010